We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Prescription drug wholesaler executives were largely evasive in response to questioning about their responsibility for the opioid crisis in a contentious House subcommittee hearing Tuesday. Read More
Treatments for particularly rare diseases such as cystic fibrosis are often given special considerations by decision-makers that may lead them to impose higher thresholds for cost-effectiveness. Read More
The Drug Enforcement Administration has ordered a Shreveport, Louisiana wholesale pharmaceutical distributor to cease sales of opioids alleging that it failed to report large, suspicious orders to drugstores. Read More
Significant price cuts would be needed for three Vertex cystic fibrosis drugs to deliver benefits equal to their cost, according to an analysis by the Institute of Clinical and Economic Review. Read More
In cases where the FDA must redact information from the Clinical Study Report, the agency will handle the process in-house rather than through a third party. Read More
Most litigation against opioid manufacturers has focused on accusations of fraud or misleading marketing that they claim contributed to the addiction crisis, but a new class-action suit holds them responsible for spiraling insurance costs. Read More
The legislation eliminated fees for supplements and establishments, as well as the establishment fee special rule that applied to establishments that manufacture positron emission tomography drugs. Read More